* 中国先声药业2096.HK周四早盘高开2.2%，随后涨幅扩大至5%。
* 该公司此前公告称，自主研发的抗肿瘤候选药物FGFR2b抗体偶联药物SIM0686已获得中国国家药品监督管理局签发的药物临床试验批准通知书，拟开展晚期实体瘤的临床试验。
* 先声药业今年迄今涨12.4%，同期恒生指数.HSI上扬5.3%。
* 恒生综合行业指数 - 医疗保健业.HSCIH盘中一度升5.9%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 林高丽)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.